|
|
|
|
Science Sparks @ ACTREC
|
 7th April 2025 |
Vol. No. 14 ; Issue No.677 |
|
|
Publications
|
|
1. Singh M, Katdare A, Ghosh S, Choudhury S, Phurailatpam R, Patil D, Tiwari M, Anaz M, Chougle N, Sable N, Agrawal A, Pawar A, Rangarajan V, Maitre P, Murthy V (2025). PSMA-PET guided Intra-prostatic Boost in Prostate SBRT (PROBE): A phase II trial. International Journal of Radiation Oncology,Biology, Physics.
2. Reddy R, Gaiwak V, Goda JS, Teni T (2025). Nelfinavir sensitizes a clinically relevant chemo-radioresistant cervical cancer in-vitro model by targeting the AKT-USP15/USP11-HPV16 E6/E7 axis. Biochemistry and Biophysics Reports. 42:101987
3. Raj J, Shah J, Ghanekar S, John G, Goda JS, Chatterjee A (2025) .Pharmacological and therapeutic innovation to mitigate Radiation-Induced Cognitive Decline (RICD) in brain tumor Patients. Cancer Letters.
4. Jeeva M, Dasgupta A, Chatterjee A, Sahu A, Sridhar E, Moiyadi A, Chinnaswamy G, Gupta T (2025). Third course of radical intent conformal radiation in patients with primary brain tumors. Clinical Oncology.
5. Katawale S, Tank S, Dhaygude H, Holm R, Shah S, Shinde U, Shidhaye S, Joshi G, Warawdekar U, Nagarsenker M (2025). Systemic delivery of Sorafenib Tosylate loaded LeciPlex®: A comparative assessment of nano assembly, biocompatibility, and in vivo drug disposition. Journal of Drug Delivery Science and Technology.
|
|
|
|
|
Interesting Reads
|
|
Raj SS, Fei T, Fried S, Ip A, Fein JA, Leslie LA, Alarcon Tomas A, Leithner D, Peled JU, Corona M, Dahi PB, Danylesko I, Epstein-Peterson Z, Funnell T, Giralt SA, Jacoby E, Kedmi M, Landego I, Lin RJ, Parascondola A, Pascual L, Orozco N, Park JH, Palomba ML, Salles G, Saldia A, Schöder H, Sdayoor I, Shah GL, Scordo M, Shem-Tov N, Shimoni A, Slingerland J, Yerushalmi R, Nagler A, Greenbaum BD, Vickers AJ, Suh HC, Avigdor A, Perales MA, van den Brink MRM, Shouval R (2025). An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma. Nature Medicine.
|
|
|
Video of the Week
|
|
| New Approaches to Hereditary Cancer Risk Assessment in Lynch Syndrome and Beyond |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 1996, FDA approved anastrozole (Arimidex) as a treatment for breast cancer. This drug blocks the production of estrogen.
|
|
|
|
Cancer News
|
| |
|
Combination immunotherapy shrank a variety of metastatic solid cancers |
|
National Cancer Institute, 01/04/2025
|
|
This form of therapy involves identifying and selecting immune cells (TILs) that are found in the tumor that specifically recognize and attack a patient’s tumor cells. Next, scientists grow those TILs into large quantities in the laboratory before they are finally administered to the patient...
|
| |
|
Scientists identify key protein driving ovarian cancer spread
|
|
MedicalXpress, 02/04/2025
|
|
ADAMTS5 functions like a pair of scissors by cleaving proteins within the extracellular matrix (ECM), the tissue surrounding tumors. This process creates pathways that enable ovarian cancer cells to migrate and invade other tissues. The research team found that inhibiting ADAMTS5 in laboratory models effectively...
|
|
|
|
|
| |
|
|
|
NSD2 gene drives cancer cell identity in multiple myeloma
|
|
EurekAlert, 02/04/2025
|
|
The study indicated that NSD2 does not directly affect the main genes responsible for plasma cell creation. Instead, it influences many other genes that help maintain the cancer cell’s identity, which contributes to cancer growth and surviva...
|
|
|
|
|
|
|
|
|
2025 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
